Ulcerative colitis trials recruiting in New York

All Ulcerative colitis trials nationally

Cities in New York

Recruiting trials in New York

• A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT06405087 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · New York: New York
• A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07185009 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · New York: Maspeth, New York
• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
  NCT04844606 · Phase: Phase 3 · Ages: 2 Years to 19 Years · Sex: All (male and female) · New York: New York
• A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
  NCT07113522 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · New York: New York, Rochester
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07196748 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · New York: Carmel, New York
• A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
  NCT05076175 · Phase: Phase 2, Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · New York: New York
• A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
  NCT06598943 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: Brooklyn, Jackson Heights, New York, Utica
• A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
  NCT07470879 · Phase: Phase 2 · Ages: 2 Years to 11 Years · Sex: All (male and female) · New York: New York
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07577856 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
  NCT07012395 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: New York
• A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
  NCT06095128 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: New York
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
  NCT06581328 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · New York: Carmel, Cedarhurst, Elmhurst, Fresh Meadows
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT05442567 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · New York: New Hyde Park, Rochester, Stony Brook
• A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
  NCT06100289 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · New York: New York
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT06588855 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · New York: Brooklyn, New York, North Massapequa, Queens Village
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
  NCT06979336 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Fresh Meadows
• A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
  NCT07158242 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · New York: Lake Success, New York
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
  NCT06867094 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: New York, Queens Village
• A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
  NCT06975722 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: New York, Queens Village
• A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
  NCT06636656 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · New York: New York
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07184996 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · New York: Maspeth, New York, The Bronx
• An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
  NCT06398626 · Phase: Not specified · Ages: 18 Years to 64 Years · Sex: All (male and female) · New York: New York
• BOOM-IBD2 Pivotal Clinical Trial
  NCT06571669 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · New York: Manhasset, New York
• Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
  NCT06651281 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · New York: New York
• Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
  NCT05987852 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · New York: New York, Syracuse
• LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
  NCT07186101 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · New York: Utica
• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
  NCT07415044 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · New York: Stony Brook
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
  NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · New York: New York, Yonkers
• Mirikizumab Real World Protocol
  NCT06696014 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: Rochester
• Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
  NCT07697456 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: New York
• Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
  NCT06750731 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT06029972 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: Brooklyn, Great Neck
• Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
  NCT06619990 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: Albany, Rochester
• Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
  NCT04314375 · Phase: Phase 4 · Ages: 5 Years to 17 Years · Sex: All (male and female) · New York: The Bronx
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Mineola, New York
• Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
  NCT05230173 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: Burnt Hills, New York, Rochester
• Zymfentra (Infliximab-dyyb) REal World Cohort STudy
  NCT07237516 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: New York